Division of Sanofi
Latest From Sanofi Pasteur
David Loew talked to Scrip about the next-generation meningococcal vaccine candidate MenQuadfi and a monoclonal antibody that may be the first RSV treatment for infants.
The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.
Dengvaxia’s Restrictive Indication Will Make Immunization Recommendations Difficult, ACIP Members Say
The need to screen individuals in dengue-endemic areas for prior infection before administering Sanofi’s vaccine will be difficult to operationalize, particularly in the absence of a reliable and rapid diagnostic, experts say; Advisory Committee on Immunization Practices working group aims for full committee vote on use recommendations in February 2020.
Vaccine specialist Hilleman announces partnership with another Indian firm, Bharat Biotech, to develop, manufacture and commercialize its simpler and cheaper oral cholera vaccine.
- Therapeutic Areas
- Infectious & Viral Diseases
- Aventis Pasteur
- Aventis Pasteur Inc.
- Western Europe
- Parent & Subsidiaries
- Senior Management
David Loew, EVP, Head
John Shiver, SVP, R&D
- Contact Info
Phone: (33) 4 37 37 01 00
14 Epsace Henry Vallee
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.